Unknown

Dataset Information

0

High Expression of ACE2 and TMPRSS2 at the Resection Margin Makes Lung Cancer Survivors Susceptible to SARS-CoV-2 With Unfavorable Prognosis.


ABSTRACT:

Background

Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide. Systematic analysis of lung cancer survivors at molecular and clinical levels is warranted to understand the disease course and clinical characteristics.

Methods

A single-center, retrospective cohort study was conducted in 65 patients with COVID-19 from Wuhan Huoshenshan Hospital, of which 13 patients were diagnosed with lung cancer. The study was conducted from February 4 to April 11, 2020.

Results

During the course of treatment, lung cancer survivors infected with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) had shorter median time from symptom onset to hospitalization (P = 0.016) and longer clinical symptom remission time (P = 0.020) than non-cancer individuals. No differences were observed among indicators such as time from symptom onset to hospitalization and symptom remission time between medium-term and short-term survivors. The expression of ACE2 (P = 0.013) and TMPRSS2 (P <0.001) was elevated in lung cancer survivors as compared with that in non-cancer individuals.

Conclusions

ACE2 and TMPRSS2 levels were higher at resection margins of lung cancer survivors than those in normal tissues of non-cancerous individuals and may serve as factors responsible for the high susceptibility to COVID-19 among lung cancer survivors. Lung cancer patients diagnosed with COVID-19, including medium-term survivors, have worse outcomes than the general population.

SUBMITTER: Wang Q 

PROVIDER: S-EPMC8176089 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

High Expression of <i>ACE2</i> and <i>TMPRSS2</i> at the Resection Margin Makes Lung Cancer Survivors Susceptible to SARS-CoV-2 With Unfavorable Prognosis.

Wang Qianqian Q   Li Liangyu L   Qu Tianyu T   Li Jie J   Wu Lingxiang L   Li Kening K   Wang Ziyu Z   Zhu Mengyan M   Huang Bin B   Wu Wei W   Wu Min M   Ding Rong R   Zhang Zhihong Z   Wang Qianghu Q   Xia Xinyi X   Li Pengping P   Zhang Zhi Z   Guo Renhua R  

Frontiers in oncology 20210521


<h4>Background</h4>Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide. Systematic analysis of lung cancer survivors at molecular and clinical levels is warranted to understand the disease course and clinical characteristics.<h4>Methods</h4>A single-center, retrospective cohort study was conducted in 65 patients with COVID-19 from Wuhan Huoshenshan Hospital, of which 13 patients were diagnosed with lung cancer. The study was conducted from February 4 to April 11, 2020.<h4>Results</h  ...[more]

Similar Datasets

| S-EPMC8242802 | biostudies-literature
| S-EPMC7794913 | biostudies-literature
2020-11-30 | GSE159576 | GEO
| S-EPMC8769877 | biostudies-literature
| S-EPMC7404937 | biostudies-literature
| S-EPMC7591870 | biostudies-literature
| S-EPMC8546705 | biostudies-literature
| S-EPMC7200365 | biostudies-literature
| S-EPMC7263499 | biostudies-literature
| S-EPMC8279956 | biostudies-literature